Navigation Links
Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
Date:5/12/2008

MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - Innolife Pharma, Inc. (Other OTC:INNP.PK - News) has been in discussion over the previous eight months regarding the formation of a joint venture partnership. INNP has reached a point in these negotiations where final written terms have been submitted on all key issues which could lead to the Company's very first product acquisition. It should be noted that this process evolved methodically over this extended period due to the successful, long term history of the product involved, and the well-established reputation of its founding corporation.

Management anticipates additional forthcoming news and progress updates on the closing of this transaction that can complete great strides in two specific areas. One is the awarding of valuable rights to Innolife Pharma of an industry leading product. This established brand known for innovation and consistency over more than two decades can be launched in a brand new target market for the first time representing the largest market of this type on a global scale. Secondly, but of equal importance, is the solidifying of a joint venture with a partner of great quality and experience. The intention is to unite the market access and distribution capabilities of INNP with the knowledge, leadership, and existing contacts of our potential joint venture partner.

INNP will continue to reveal details of our aggressive strategy geared towards long term growth as they become available. We are confident that a partnership will emerge and start to bring in revenue in the near term based on the high level of negotiations reached with an industry leader in the information technology field. The Company believes that the size of our target market is potentially in excess of US$20 Billion. Updates will also be available on the Company's official corporate web site at http://www.innolifepharma.com. Please bear with us as the site is still under development, but will be officially launched upon finalization of our partnership and product acquisition.

FORWARD-LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE Innolife Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
2. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
3. Par Pharmaceutical Reports First Quarter 2008 Results
4. IDM Pharma Reports First Quarter Financial Results
5. Vion Pharmaceuticals to Appeal Nasdaq Delisting
6. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
7. Patients, Doctors, Pharmacists Praise Bipartisan House Resolution on Compounded Hormones Containing Estriol
8. AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company
9. Par Pharmaceutical Acquires Spectrum Pharmaceuticals Interest In Sumatriptan Injection
10. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
11. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Newark, NJ (PRWEB) , ... April 28, 2017 , ... ... Poor’s has affirmed the company’s credit rating of “A” and its outlook as “stable.” ... downgraded if capital reserves, which have fallen in recent years, dip below “capital adequacy” ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today a ... the Northeast U.S. , GlycoMark is the only clinically available blood test ... a clinically proven one- to two-week measure of hyperglycemic excursions, often related to ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... that Aditya Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. ... certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used ...
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
Breaking Medicine News(10 mins):
(Date:4/26/2017)... Phoenix Marketing Solutions ( Phoenix ) ... mission of transforming science into clinical practice. During a time ... innovative approach supports the life sciences industry by ... in science and medicine — which ultimately improves lives. ... 2002 by Tracy Doyle and Angela Fiordilino ...
(Date:4/20/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... and Gynecology markets with innovative and proprietary products, ... Company as Senior Vice President, Marketing & Business ... will report directly to Darin Hammers , ... delighted that Ash has joined the Cogentix team," ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
Breaking Medicine Technology: